LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.84 0.21

Buy Sell

Overview

Share price change

24h

Current

Min

4.77

Max

5.02

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+191.55% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	-26M 229M
Previous open	4.63
Previous close	4.84

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 mar 2026, 23:12 UTC

Hot Stocks

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12 mar 2026, 22:15 UTC

Earnings

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12 mar 2026, 21:42 UTC

Major News Events

Stryker Says Cyberattack Disruption Is Continuing

12 mar 2026, 21:29 UTC

Major News Events

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12 mar 2026, 21:27 UTC

Earnings

Adobe CEO to Depart as AI Boosts Sales -- Update

12 mar 2026, 20:46 UTC

Earnings

Adobe Posts Higher Sales With CEO Set to Depart

12 mar 2026, 20:21 UTC

Major News Events

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12 mar 2026, 23:57 UTC

Market Talk

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12 mar 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 mar 2026, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12 mar 2026, 22:13 UTC

Earnings

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12 mar 2026, 22:13 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

12 mar 2026, 22:13 UTC

Market Talk

Earnings

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12 mar 2026, 21:16 UTC

Acquisitions, Mergers, Takeovers

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12 mar 2026, 21:04 UTC

Earnings

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12 mar 2026, 21:02 UTC

Earnings

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12 mar 2026, 21:02 UTC

Earnings

Wheaton Precious Metals 4Q Sales $865M >WPM

12 mar 2026, 21:02 UTC

Earnings

Wheaton Precious Metals 4Q Net $558.3M >WPM

12 mar 2026, 21:02 UTC

Earnings

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12 mar 2026, 20:57 UTC

Market Talk

Major News Events

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12 mar 2026, 20:10 UTC

Earnings

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12 mar 2026, 20:05 UTC

Earnings

Adobe 1Q Rev $6.4B >ADBE

12 mar 2026, 20:05 UTC

Earnings

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

191.55% upside

12 Months Forecast

Average 14.14 USD 191.55%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.